Lixisenatide is a well-tolerated GLP-1R agonist that can be administered by injection once-daily. This clinical trial aims to assess the effects of lixisenatide, versus placebo, on both motor and non-motor symptoms in people with early stage Parkinson’s.
We are sorry that this content was not useful for you
Let us improve this content
Can you tell us how we can improve this content?